StockData
InMed Pharmaceuticals Inc. logo

InMed Pharmaceuticals Inc. (MTRI) stock

MTRINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as INM
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 4/30
$17.50−2.37 (-11.93%)

Close on Nov 17, 2026Market cap $96.14MP/E –Yield –

InMed Pharmaceuticals gross margin

Gross margin is gross profit as a percentage of revenue.

InMed Pharmaceuticals's gross margin for the twelve months ending Dec 31, 2025 was 29.7%. For fiscal 2025 it was 34.5%, against 23.9% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Jun 30, 202534.5%+10.6
FY2024Jun 30, 202423.9%−10.0
FY2023Jun 30, 202333.9%−16.0
FY2022Jun 30, 202249.9%–

Quarterly gross margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q2 FY2026CQ4 2025Dec 31, 202522.5%−19.0
Q1 FY2026CQ3 2025Sep 30, 202536.0%−3.0
Q4 FY2025CQ2 2025Jun 30, 202544.2%+7.9
Q3 FY2025CQ1 2025Mar 31, 202513.9%−10.8
Q2 FY2025CQ4 2024Dec 31, 202441.5%+15.3
Q1 FY2025CQ3 2024Sep 30, 202439.0%+36.7
Q4 FY2024CQ2 2024Jun 30, 202436.3%−31.6
Q3 FY2024CQ1 2024Mar 31, 202424.7%+6.1
Q2 FY2024CQ4 2023Dec 31, 202326.1%−1.8
Q1 FY2024CQ3 2023Sep 30, 20232.4%+155.4
Q4 FY2023CQ2 2023Jun 30, 202368.0%+19.4
Q3 FY2023CQ1 2023Mar 31, 202318.6%−40.3
Q2 FY2023CQ4 2022Dec 31, 202227.9%−14.2
Q1 FY2023CQ3 2022Sep 30, 2022-153.1%–
Q4 FY2022CQ2 2022Jun 30, 202248.5%–
Q3 FY2022CQ1 2022Mar 31, 202258.9%–
Q2 FY2022CQ4 2021Dec 31, 202142.1%–

More InMed Pharmaceuticals figures

See a number that looks wrong?